150 related articles for article (PubMed ID: 22289258)
1. CYP2C9 promoter variable number tandem repeat polymorphism regulates mRNA expression in human livers.
Wang D; Sun X; Gong Y; Gawronski BE; Langaee TY; Shahin MH; Khalifa SI; Johnson JA
Drug Metab Dispos; 2012 May; 40(5):884-91. PubMed ID: 22289258
[TBL] [Abstract][Full Text] [Related]
2. Frequency of
Dorado P; Santos-Díaz G; Gutiérrez-Martín Y; Suárez-Santisteban MÁ
J Pers Med; 2022 May; 12(5):. PubMed ID: 35629204
[TBL] [Abstract][Full Text] [Related]
3. The impact of genetic polymorphisms and patient characteristics on warfarin dose requirements: a cross-sectional study in Iran.
Namazi S; Azarpira N; Hendijani F; Khorshid MB; Vessal G; Mehdipour AR
Clin Ther; 2010 Jun; 32(6):1050-60. PubMed ID: 20637959
[TBL] [Abstract][Full Text] [Related]
4. CYP2C9 promoter region single-nucleotide polymorphisms linked to the R150H polymorphism are functional suggesting their role in CYP2C9*8-mediated effects.
Cavallari LH; Vaynshteyn D; Freeman KM; Wang D; Perera MA; Takahashi H; Drozda K; Patel SR; Jeong H
Pharmacogenet Genomics; 2013 Apr; 23(4):228-31. PubMed ID: 23376925
[TBL] [Abstract][Full Text] [Related]
5. CYP2C9*1B promoter polymorphisms, in linkage with CYP2C19*2, affect phenytoin autoinduction of clearance and maintenance dose.
Chaudhry AS; Urban TJ; Lamba JK; Birnbaum AK; Remmel RP; Subramanian M; Strom S; You JH; Kasperaviciute D; Catarino CB; Radtke RA; Sisodiya SM; Goldstein DB; Schuetz EG
J Pharmacol Exp Ther; 2010 Feb; 332(2):599-611. PubMed ID: 19855097
[TBL] [Abstract][Full Text] [Related]
6. The impact of CYP2C9 and VKORC1 genetic polymorphism and patient characteristics upon warfarin dose requirements in an adult Turkish population.
Ozer N; Cam N; Tangurek B; Ozer S; Uyarel H; Oz D; Guney MR; Ciloglu F
Heart Vessels; 2010 Mar; 25(2):155-62. PubMed ID: 20339978
[TBL] [Abstract][Full Text] [Related]
7. VKORC1 and CYP2C9 genotypes are predictors of warfarin-related outcomes in children.
Shaw K; Amstutz U; Hildebrand C; Rassekh SR; Hosking M; Neville K; Leeder JS; Hayden MR; Ross CJ; Carleton BC
Pediatr Blood Cancer; 2014 Jun; 61(6):1055-62. PubMed ID: 24474498
[TBL] [Abstract][Full Text] [Related]
8. 5'-Flanking region polymorphisms of CYP2C9 and their relationship to S-warfarin metabolism in white and Japanese patients.
Takahashi H; Ieiri I; Wilkinson GR; Mayo G; Kashima T; Kimura S; Otsubo K; Echizen H
Blood; 2004 Apr; 103(8):3055-7. PubMed ID: 15070684
[TBL] [Abstract][Full Text] [Related]
9. Influence of CYP2C9 and VKORC1 polymorphisms on warfarin and acenocoumarol in a sample of Lebanese people.
Esmerian MO; Mitri Z; Habbal MZ; Geryess E; Zaatari G; Alam S; Skouri HN; Mahfouz RA; Taher A; Zgheib NK
J Clin Pharmacol; 2011 Oct; 51(10):1418-28. PubMed ID: 21148049
[TBL] [Abstract][Full Text] [Related]
10. VKORC1 gene variations are the major contributors of variation in warfarin dose in Japanese patients.
Obayashi K; Nakamura K; Kawana J; Ogata H; Hanada K; Kurabayashi M; Hasegawa A; Yamamoto K; Horiuchi R
Clin Pharmacol Ther; 2006 Aug; 80(2):169-78. PubMed ID: 16890578
[TBL] [Abstract][Full Text] [Related]
11. Upstream and coding region CYP2C9 polymorphisms: correlation with warfarin dose and metabolism.
King BP; Khan TI; Aithal GP; Kamali F; Daly AK
Pharmacogenetics; 2004 Dec; 14(12):813-22. PubMed ID: 15608560
[TBL] [Abstract][Full Text] [Related]
12. Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.
Borgiani P; Ciccacci C; Forte V; Romano S; Federici G; Novelli G
Pharmacogenomics; 2007 Nov; 8(11):1545-50. PubMed ID: 18034619
[TBL] [Abstract][Full Text] [Related]
13. Association between the CYP2C9 polymorphism and the drug metabolism phenotype.
Topić E; Stefanović M; Samardzija M
Clin Chem Lab Med; 2004 Jan; 42(1):72-8. PubMed ID: 15061384
[TBL] [Abstract][Full Text] [Related]
14. Warfarin metabolism and anticoagulant effect: a prospective, observational study of the impact of CYP2C9 genetic polymorphism in the presence of drug-disease and drug-drug interactions.
Muszkat M; Blotnik S; Elami A; Krasilnikov I; Caraco Y
Clin Ther; 2007 Mar; 29(3):427-37. PubMed ID: 17577464
[TBL] [Abstract][Full Text] [Related]
15. Impact of CYP2C9 genetic polymorphism on warfarin dose requirements in Pakistani population.
Siddiqi A; Khan DA; Khan FA; Naveed AK
Pak J Pharm Sci; 2010 Oct; 23(4):417-22. PubMed ID: 20884456
[TBL] [Abstract][Full Text] [Related]
16. Effect of CYP2C9 and VKORC1 genetic variations on warfarin dose requirements in Indian patients.
Natarajan S; Ponde CK; Rajani RM; Jijina F; Gursahani R; Dhairyawan PP; Ashavaid TF
Pharmacol Rep; 2013; 65(5):1375-82. PubMed ID: 24399734
[TBL] [Abstract][Full Text] [Related]
17. Genetic and clinical determinants influencing warfarin dosing in children with heart disease.
Nguyen N; Anley P; Yu MY; Zhang G; Thompson AA; Jennings LJ
Pediatr Cardiol; 2013 Apr; 34(4):984-90. PubMed ID: 23183958
[TBL] [Abstract][Full Text] [Related]
18. Genotypes of the cytochrome p450 isoform, CYP2C9, and the vitamin K epoxide reductase complex subunit 1 conjointly determine stable warfarin dose: a prospective study.
Carlquist JF; Horne BD; Muhlestein JB; Lappé DL; Whiting BM; Kolek MJ; Clarke JL; James BC; Anderson JL
J Thromb Thrombolysis; 2006 Dec; 22(3):191-7. PubMed ID: 17111199
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of the warfarin-resistance polymorphism, VKORC1 Asp36Tyr, and its effect on dosage algorithms in a genetically heterogeneous anticoagulant clinic.
Shuen AY; Wong BY; Fu L; Selby R; Cole DE
Clin Biochem; 2012 Apr; 45(6):397-401. PubMed ID: 22266406
[TBL] [Abstract][Full Text] [Related]
20. In-vitro and in-vivo effects of the CYP2C9*11 polymorphism on warfarin metabolism and dose.
Tai G; Farin F; Rieder MJ; Dreisbach AW; Veenstra DL; Verlinde CL; Rettie AE
Pharmacogenet Genomics; 2005 Jul; 15(7):475-81. PubMed ID: 15970795
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
